Aminoglycosides are a class of antibiotics commonly used to treat severe bacterial infections, but their use carries a significant risk of ototoxicity, especially in individuals with certain genetic predispositions. One such factor is the MT-RNR1 gene mutation, specifically the m.1555G variant, which greatly increases the risk of aminoglycoside-induced hearing loss. Early detection of this genetic variant is essential to prevent irreversible hearing damage in patients requiring aminoglycoside treatment.

Current genetic testing methods are limited by long processing times and the need for specialized laboratory facilities, highlighting the urgent need for a rapid, reliable, and accessible testing solution.